Adjustment of the nominal value: Neovacs reduces its capital

Neovacs, a preclinical biopharmaceutical company listed on Euronext Growth Paris (ALNEV), announced on June 28, 2024 a capital reduction driven by losses. The Board of Directors, following the 13th resolution voted at the General Meeting of June 27, 2024, has decided to reduce the nominal value of its shares.

The nominal value of the share is reduced from 0.005 euros to 0.0005 euros. Consequently, the share capital of the Company, initially 1,259,680.985 euros for 251,936,197 shares, is now reduced to 125,968.0985 euros.